Collecting samples and data from sarcoma patients on immunotherapy
Part of Cancer clinical trials.
This study collects tissue samples and medical data from people with sarcoma who are receiving or will receive immunotherapy. Its goal is to learn more about how these treatments work against sarcoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of sarcoma confirmed by a doctor at Memorial Sloan Kettering.
- You are going to receive or are already receiving immunotherapy, such as a PD-1, PD-L1, CTLA-4, or LAG3 blocker, or a special cell therapy like lifileucel or afamitresgene autoleucel.
- You must agree to let the study collect your medical records and samples from before, during, and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
This study collects information and blood samples from adults with sarcoma who had surgery and possibly radiation. The goal is to build a large dataset that helps researchers understand sarcoma better and improve future care.
This trial tests a combination of immune cells targeting sarcoma tumors. It is for people with advanced or recurrent sarcoma who have not responded well to standard treatments.
This study collects tumor (or related) samples to analyze their genes and build a shared research “biobank.” It may help researchers understand cancers better for future diagnosis and treatments.
This study gathers information from people diagnosed with sarcoma (a bone or soft-tissue cancer) and their family members to learn what life is like after diagnosis. It is open to patients of any age, as well as their parents, caregivers, and older siblings.
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.